We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
(-16%)
Cap. Flow
+$98.4M
Cap. Flow
% of AUM
8.63%
Top 10 Holdings %
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
4.1
quarters
Top 20 Avg Time Held Equity + Options
4.2
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
4.1
quarters
Top 20 Avg Time Held Equity only
4.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$27.8M |
| 2 |
Humana
HUM
|
+$19.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$15.3M |
| 4 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$13.2M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$68.4M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$12.9M |
| 3 |
Baxter International
BAX
|
+$10.1M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$8.54M |
| 5 |
NEVRO CORP.
NVRO
|
+$8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.87% |
| 2 | Miscellaneous | 6.35% |
| 3 | Consumer Staples | 0.6% |
| 4 | Consumer Discretionary | 0.11% |
| 5 | Industrials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
Curis
CRIS
$1.49M
| $161K | 0.01% |
50
| – | – |
2015 Q3
2 quarters
|
|
152
DELISTED
Fonar
FONR
| $130K | 0.01% |
8,473
| – | – |
2015 Q4
1 quarter
|
|
|
GI
153
DELISTED
EndoChoice Holdings, Inc.
GI
| $130K | 0.01% |
+25,000
| New | +$137K |
2016 Q1
0 quarters
|
|
154
Myriad Genetics
MYGN
$390M
| $125K | 0.01% |
3,333
+833
| +33% | +$31.4K |
2015 Q2
3 quarters
|
|
155
DELISTED
Star Equity Holdings
STRR
| $124K | 0.01% |
500
| – | – |
2015 Q4
1 quarter
|
|
156
DELISTED
Adverum Biotechnologies
ADVM
| $103K | 0.01% |
+2,000
| New | +$112K |
2016 Q1
0 quarters
|
|
157
Cellectis
CLLS
$111M
| $82K | 0.01% |
2,996
| – | – |
2015 Q1
4 quarters
|
|
158
Herbalife
HLF
$1.49B
| $77K | 0.01% |
+2,500
| New | +$64.5K |
2016 Q1
0 quarters
|
|
159
DELISTED
Catalyst Pharmaceutical
CPRX
| $60K | 0.01% |
51,200
-800,000
| -94% | -$1.24M |
2015 Q1
4 quarters
|
|
|
NSPH
160
DELISTED
NANOSPHERE INC. COM NEW
NSPH
| $28K | ﹤0.01% |
35,379
| – | – |
2015 Q2
3 quarters
|
|
161
Zimmer Biomet
ZBH
$17.6B
| $17K | ﹤0.01% |
+161
| New | +$15.6K |
2016 Q1
0 quarters
|
|
162
Capricor Therapeutics
CAPR
$400M
| $10K | ﹤0.01% |
400
| – | – |
2015 Q1
4 quarters
|
|
163
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $10K | ﹤0.01% |
+3,476
| New | +$18.6K |
2016 Q1
0 quarters
|
|
|
SCMP
164
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $8K | ﹤0.01% |
759
| – | – |
2015 Q3
2 quarters
|
|
165
Inogen
INGN
$168M
| $6K | ﹤0.01% |
125
| – | – |
2015 Q4
1 quarter
|
|
166
Decoy Therapeutics
DCOY
$812K
| – | – |
0
| – | – |
2015 Q4
1 quarter
|
|
167
DELISTED
Affimed
AFMD
| – | – |
-86,882
| Closed | -$6.19M | – |
|
168
DELISTED
Accelerate Diagnostics
AXDX
| – | – |
-75
| Closed | -$16K | – |
|
169
Biogen
BIIB
$33.8B
| – | – |
-648
| Closed | -$199K | – |
|
170
Cigna
CI
$74.7B
| – | – |
-20,000
| Closed | -$2.93M | – |
|
171
Cencora
COR
$63B
| – | – |
-2,030
| Closed | -$211K | – |
|
172
CorVel
CRVL
$3.98B
| – | – |
-15,345
| Closed | -$225K | – |
|
173
Community Health Systems
CYH
$422M
| – | – |
-8,136
| Closed | -$178K | – |
|
174
The Ensign Group
ENSG
$10.1B
| – | – |
-9,347
| Closed | -$198K | – |
|
175
ImmunityBio
IBRX
$10.4B
| – | – |
-10,000
| Closed | -$173K | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2016 Portfolio in Review
As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $98.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $12.9M trimmed.
- Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
- Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $12.9M.
- Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
- Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
- Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
- Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.
Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.